Get started
Author

Eduard Puente‐Massaguer

Observed names: E. Puente-Massaguer, Eduard Puente Massaguer, Eduard Puente-Massaguer, Puente-Massaguer, Eduard
ORCID: 0000-0002-2816-7051
Observed ORCID: 0000-0002-2816-7051
OpenAlex ID: A5084134236
Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
2022 · Meagan McMahon, George O’Dell, et al. · Proceedings of the National Academy of Sciences · 82
Quality Assessment of Virus-Like Particles at Single Particle Level: A Comparative Study
2020 · Irene González-Domínguez, Eduard Puente-Massaguer, et al. · Viruses · 52
PDF
Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice
2023 · Eduard Puente-Massaguer, Kirill Vasilev, et al. · Science Advances · 36
Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products
2018 · Clémentine Mirabel, Eduard Puente-Massaguer, et al. · Journal of Translational Medicine · 30
PDF
Application of advanced quantification techniques in nanoparticle-based vaccine development with the Sf9 cell baculovirus expression system
2020 · Eduard Puente-Massaguer, Martí Lecina, et al. · Vaccine · 29
Nanoscale characterization coupled to multi-parametric optimization of Hi5 cell transient gene expression
2018 · Eduard Puente-Massaguer, Martí Lecina, et al. · Applied Microbiology and Biotechnology · 28
Micrometric DNA/PEI polyplexes correlate with higher transient gene expression yields in HEK 293 cells
2022 · Irene González-Domínguez, Eduard Puente-Massaguer, et al. · New Biotechnology · 26
PDF
Development of a non-viral platform for rapid virus-like particle production in Sf9 cells
2020 · Eduard Puente-Massaguer, Francesc Gòdia, et al. · Journal of Biotechnology · 25
PDF
A statistical approach to improve compound screening in cell culture media
2019 · Eduard Puente‐Massaguer, Llorenç Badiella, et al. · Engineering in Life Sciences · 25
PDF
Quantification of the HIV‐1 virus‐like particle production process by super‐resolution imaging: From VLP budding to nanoparticle analysis
2020 · Irene González‐Domínguez, Eduard Puente‐Massaguer, et al. · Biotechnology and Bioengineering · 23
Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface
2022 · Xueyong Zhu, Julianna Han, et al. · Proceedings of the National Academy of Sciences · 22
Integrating nanoparticle quantification and statistical design of experiments for efficient HIV-1 virus-like particle production in High Five cells
2020 · Eduard Puente-Massaguer, Martí Lecina, et al. · Applied Microbiology and Biotechnology · 22
PDF
PEI-Mediated Transient Transfection of High Five Cells at Bioreactor Scale for HIV-1 VLP Production
2020 · Eduard Puente-Massaguer, Florian Strobl, et al. · Nanomaterials · 20
PDF
Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses
2023 · Willemijn Frederique Rijnink, Daniel Stadlbauer, et al. · Journal of Virology · 18
PDF
Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants
2025 · Kirill Vasilev, Irene Hoxie, et al. · npj Vaccines · 17
PDF
Accelerating HIV‐1 VLP production using stable High Five insect cell pools
2020 · Eduard Puente‐Massaguer, Paula Grau‐Garcia, et al. · Biotechnology Journal · 17
Transduction of HEK293 Cells with BacMam Baculovirus Is an Efficient System for the Production of HIV-1 Virus-like Particles
2022 · Eduard Puente-Massaguer, Byron Cajamarca-Berrezueta, et al. · Viruses · 13
PDF
Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach
2024 · Irene González-Domínguez, Eduard Puente-Massaguer, et al. · npj Vaccines · 11
Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses
2023 · Eduard Puente-Massaguer, Annika Beyer, et al. · Frontiers in Bioengineering and Biotechnology · 11
The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex
2024 · Jose L. Martínez, Nicholas Lemus, et al. · Vaccine · 9
PDF
Coupling Microscopy and Flow Cytometry for a Comprehensive Characterization of Nanoparticle Production in Insect Cells
2020 · Eduard Puente‐Massaguer, Paolo Saccardo, et al. · Cytometry Part A · 8
PDF
Bioprocess characterization of virus‐like particle production with the insect cell baculovirus expression system at nanoparticle level
2022 · Eduard Puente‐Massaguer, Irene González‐Domínguez, et al. · Journal of Chemical Technology & Biotechnology · 7
PDF
An H5N1 clade 2.3.4.4b virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins
2026 · Eduard Puente-Massaguer, Thales Galdino Andrade, et al. · Nature Communications · 6
Stable Sf9 cell pools as a system for rapid HIV ‐1 virus‐like particle production
2021 · Eduard Puente‐Massaguer, Paula Grau‐Garcia, et al. · Journal of Chemical Technology & Biotechnology · 5
A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responses
2026 · Irene Hoxie, Kirill Vasilev, et al. · npj Vaccines · 3
PDF
Works count: 42
Citation count: 559
H-index: 16
I10-index: 19
Year
Topic
Type